Neurological drugs developer Karuna Therapeutics is building up its pipeline with a pair of molecules initially developed for kidney disorders. It’s a small bet that could pay off in a big way by ...

Bristol Myers Squibb spent $14 billion in December on neurology biotech Karuna and its schizophrenia drug-in-waiting KarXT; now the focus is on launch plans and creating a franchise in a drug that ...

Drugmaker Bristol Myers BMY0.67%increase; green up pointing triangle Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would pay ...

Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimer’s drugmaker Karuna Therapeutics for $14 billion. Bristol Myers said it would pay $330 a share cash for ...

William Blair notes increasing investor inbounds on Karuna Therapeutics Inc (NASDAQ:KRTX) given the recent pullback, as the stock is down 13% off June 2023 highs and 25% off 52-week highs after the ...

Bristol Myers Squibb (NYSE:BMY) out-maneuvered another large multinational pharmaceutical company in its $14B deal to acquire neurology-focused Karuna Therapeutics (KRTX) last month in a hard-won ...

The fate of Karuna’s schizophrenia drug, KarXT, now rests with U.S. regulators after the company formally submitted its new drug application Thursday. The company had been projecting a third-quarter ...

The deal is a bet on the growing market for psychiatric and neurological drugs. By Lauren Hirsch Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna ...

Karuna Therapeutics is gearing up for a potential launch of schizophrenia med KarXT—one analysts say could be “amongst the highest in profile in recent times.” But it’ll now be doing it without its ...